Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission

 
• By Joseph Haas
  
CKD Reata image
CRL is Reata's latest setback in R&D for rare forms of chronic kidney disease • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip